Literature DB >> 9135893

Palliative radiotherapy for lung cancer: two versus five fractions.

G J Rees1, C E Devrell, V L Barley, H F Newman.   

Abstract

The aim of this prospective randomized trial was to compare the symptomatic effects of two different regimens of palliative radiotherapy for lung cancer. Two hundred and sixteen patients needing palliation were randomized to receive either a 17 Gy mid-point dose in two fractions 1 week apart or 22.5 Gy in five daily fractions. Both toxicity and efficacy were evaluated by postal questionnaires. This small study was intended to identify any clinically important differences in toxicity or efficacy between the two regimens. We detected no such difference, although there was a tendency for iatrogenic dysphagia and improvement in chest pain and cough to be more common with the two-fraction regimen. The only symptom that was improved in over 50% of patients for 8 weeks or more was haemoptysis. Haemoptysis and chest pain appeared to be the best indications for treatment. The relief of other symptoms was disappointing in both degree and duration.

Entities:  

Mesh:

Year:  1997        PMID: 9135893     DOI: 10.1016/s0936-6555(05)80446-7

Source DB:  PubMed          Journal:  Clin Oncol (R Coll Radiol)        ISSN: 0936-6555            Impact factor:   4.126


  16 in total

1.  Palliative Hypofractionated Radiotherapy For Non-small-cell Lung Cancer (NSCLC) Patients Previously Treated By Induction Chemotherapy.

Authors:  George A Plataniotis; Maria-Aikaterini Theofanopoulou; Konstantinia Sotiriadou; Kyriaki Theodorou; Panagiotis Mavroidis; George Kyrgias
Journal:  J Thorac Dis       Date:  2009-12       Impact factor: 2.895

Review 2.  Palliative radiotherapy regimens for patients with thoracic symptoms from non-small cell lung cancer.

Authors:  Rosemary Stevens; Fergus Macbeth; Elizabeth Toy; Bernadette Coles; Jason F Lester
Journal:  Cochrane Database Syst Rev       Date:  2015-01-14

3.  Has the practice of radiation oncology for locally advanced and metastatic non-small-cell lung cancer changed in Canada?

Authors:  K Han; A Bezjak; W Xu; G Kane
Journal:  Curr Oncol       Date:  2010-02       Impact factor: 3.677

4.  Does high-dose radiotherapy benefit palliative lung cancer patients?: An intradepartmental comparison of two dose regimens.

Authors:  C Schröder; M Ivo; A Buchali
Journal:  Strahlenther Onkol       Date:  2013-05-31       Impact factor: 3.621

Review 5.  Current landscape of palliative radiotherapy for non-small-cell lung cancer.

Authors:  Raphael Jumeau; Florent Vilotte; André-Dante Durham; Esat-Mahmut Ozsahin
Journal:  Transl Lung Cancer Res       Date:  2019-09

6.  Radiobiological prediction of normal tissue toxicities and tumour response in the radiotherapy of advanced non-small-cell lung cancer.

Authors:  J M Singer; P Price; R G Dale
Journal:  Br J Cancer       Date:  1998-12       Impact factor: 7.640

7.  A prospective, randomised study to compare two palliative radiotherapy schedules for non-small-cell lung cancer (NSCLC).

Authors:  E Senkus-Konefka; R Dziadziuszko; E Bednaruk-Młyński; A Pliszka; J Kubrak; A Lewandowska; K Małachowski; M Wierzchowski; M Matecka-Nowak; J Jassem
Journal:  Br J Cancer       Date:  2005-03-28       Impact factor: 7.640

8.  Quality of life measurement in cancer patients receiving palliative radiotherapy for symptomatic lung cancer: a literature review.

Authors:  N Salvo; S Hadi; J Napolskikh; P Goh; E Sinclair; E Chow
Journal:  Curr Oncol       Date:  2009-03       Impact factor: 3.677

9.  Clinical management of pain in advanced lung cancer.

Authors:  Claribel P L Simmons; Nicholas Macleod; Barry J A Laird
Journal:  Clin Med Insights Oncol       Date:  2012-10-08

10.  Efficacy and Survival after Palliative Radiotherapy for Malignant Pulmonary Obstruction.

Authors:  Adam G Johnson; Michael H Soike; Michael K Farris; Ryan T Hughes
Journal:  J Palliat Med       Date:  2021-07-13       Impact factor: 2.947

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.